Literature DB >> 18162804

Risk assessment to guide the prevention of cervical cancer.

Philip E Castle1, Mario Sideri, Jose Jeronimo, Diane Solomon, Mark Schiffman.   

Abstract

Advances in screening and diagnosis make it increasingly possible to prevent cervical cancer. However, if misused or poorly understood, these new tools will only increase costs and potentially harm patients without benefit. As a framework for standardized care that maximizes patient safety and well-being, we propose that a risk model be adopted to guide clinical management now and in the future. The model would use thresholds of increasing risk for cervical precancer and treatable cancer to guide clinical decision making for screening intensity, diagnostic evaluation, or treatment. Experts would decide on these risk thresholds and stratum based on the patient risk to benefit, independent of current (e.g., cytology, carcinogenic human papillomavirus testing, and colposcopy) and future methods of measuring risk. A risk management model for cervical cancer prevention, based on appropriate clinical actions that correspond to risk stratum, can result in better allocation of resources to and increased safety for women at the greatest risk and increased well-being for women at the lowest risk.

Entities:  

Mesh:

Year:  2008        PMID: 18162804     DOI: 10.1097/lgt.0b013e31815ea58b

Source DB:  PubMed          Journal:  J Low Genit Tract Dis        ISSN: 1089-2591            Impact factor:   1.925


  18 in total

1.  Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results.

Authors:  Philip E Castle; Walter K Kinney; Xiaonan Xue; Li C Cheung; Julia C Gage; Nancy E Poitras; Thomas S Lorey; Hormuzd A Katki; Nicolas Wentzensen; Mark Schiffman
Journal:  J Natl Cancer Inst       Date:  2019-08-01       Impact factor: 13.506

2.  The road ahead for cervical cancer prevention and control.

Authors:  J E Tota; A V Ramana-Kumar; Z El-Khatib; E L Franco
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

3.  Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines.

Authors:  Hormuzd A Katki; Mark Schiffman; Philip E Castle; Barbara Fetterman; Nancy E Poitras; Thomas Lorey; Li C Cheung; Tina Raine-Bennett; Julia C Gage; Walter K Kinney
Journal:  J Low Genit Tract Dis       Date:  2013-04       Impact factor: 1.925

4.  Screening: A risk-based framework to decide who benefits from screening.

Authors:  Philip E Castle; Hormuzd A Katki
Journal:  Nat Rev Clin Oncol       Date:  2016-06-21       Impact factor: 66.675

5.  Negative predictive value of pap testing: implications for screening intervals for women with human immunodeficiency virus.

Authors:  L Stewart Massad; Gypsyamber DʼSouza; Fang Tian; Howard Minkoff; Mardge Cohen; Rodney L Wright; Christine Colie; Nancy A Hessol
Journal:  Obstet Gynecol       Date:  2012-10       Impact factor: 7.661

6.  Why does cervical cancer occur in a state-of-the-art screening program?

Authors:  Philip E Castle; Walter K Kinney; Li C Cheung; Julia C Gage; Barbara Fetterman; Nancy E Poitras; Thomas S Lorey; Nicolas Wentzensen; Brian Befano; John Schussler; Hormuzd A Katki; Mark Schiffman
Journal:  Gynecol Oncol       Date:  2017-06-10       Impact factor: 5.482

7.  Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women.

Authors:  Renée Mf Ebisch; Judith van der Horst; Meyke Hermsen; L Lucia Rijstenberg; Judith Em Vedder; Johan Bulten; Remko P Bosgraaf; Viola Mj Verhoef; Daniëlle Am Heideman; Peter Jf Snijders; Chris Jlm Meijer; Folkert J van Kemenade; Leon Fag Massuger; Willem Jg Melchers; Ruud Lm Bekkers; Albert G Siebers
Journal:  Mod Pathol       Date:  2017-03-17       Impact factor: 7.842

8.  Optimizing technology for cervical cancer screening in high-resource settings.

Authors:  Lyndsay A Richardson; Joseph Tota; Eduardo L Franco
Journal:  Expert Rev Obstet Gynecol       Date:  2011-05

9.  Assessing 10-Year Safety of a Single Negative HPV Test for Cervical Cancer Screening: Evidence from FOCAL-DECADE Cohort.

Authors:  Anna Gottschlich; Dirk van Niekerk; Laurie W Smith; Lovedeep Gondara; Joy Melnikow; Darrel A Cook; Marette Lee; Gavin Stuart; Ruth E Martin; Stuart Peacock; Eduardo L Franco; Andrew Coldman; Mel Krajden; Gina Ogilvie
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-10-20       Impact factor: 4.254

10.  Comparative risk of high-grade histopathology diagnosis after a CIN 1 finding in endocervical curettage versus cervical biopsy.

Authors:  Julia C Gage; Máire A Duggan; Jill G Nation; Song Gao; Philip E Castle
Journal:  J Low Genit Tract Dis       Date:  2013-04       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.